CCR5 antagonist Maraviroc 143 is now used clinically, alongside other drugs, to delay progression to AIDS in HIV‐positive patients, and there was considerable publicity when transplantation of HLA‐matched stem cells from Δ32‐CCR5 homozygotes proved very effective in treating an HIV‐infected patient 144. Here, CCR5 is linked to AIDS.